Denver-based market research startup GutCheck has found $4 million for a Series B round of financing. The deal provides more resources to the company whose software helps companies conduct one-on-one surveys with consumers with greater speed than traditional methods of gathering such information, CEO Matt Warta tells Xconomy. The U.S. drug giant Pfizer ($PFE) and other companies outside of the pharma business have used GutCheck's service. Article